Arrowhead Pharmaceuticals (ARWR)
(Real Time Quote from BATS)
$25.15 USD
-0.54 (-2.10%)
Updated Jun 28, 2024 09:56 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Arrowhead Pharmaceuticals, Inc. [ARWR]
Reports for Purchase
Showing records 81 - 92 ( 92 total )
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Neutral Lowering to Neutral on reaching price target
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Reported financial results for their Q3/2013 quarter
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
Initiating coverage with a BUY rating and 12-18 month price target of $4.00 per share
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Arrowhead Pharmaceuticals, Inc.
Industry: Nanotechnology
A FOUR STAR PATENTVEST IP VALUE COMPANY -2011 "BEST AND BRIGHTEST" PATENTVEST REPORTS
Provider: MDB CAPITAL GROUP LLC